Mediolanum International Funds Ltd Takes $10.40 Million Position in Novo Nordisk A/S $NVO

Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 151,856 shares of the company’s stock, valued at approximately $10,404,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at $30,000. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Disciplina Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $37,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NVO shares. Hsbc Global Res raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Monday. HSBC set a $70.00 price target on Novo Nordisk A/S in a report on Wednesday, October 1st. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $47.65 on Friday. The business has a fifty day moving average price of $53.92 and a two-hundred day moving average price of $60.38. The stock has a market capitalization of $212.76 billion, a PE ratio of 13.09, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.